

UCLA

UCLA Previously Published Works

Title

Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

Permalink

<https://escholarship.org/uc/item/1r57187f>

Journal

Advances in Therapy, 34(7)

ISSN

0741-238X

Authors

Adsit, Sandra

Zaldivar, Enrique Rivas

Sofen, Howard

et al.

Publication Date

2017-07-01

DOI

10.1007/s12325-017-0563-2

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

ERRATUM

Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

Sandra Adsit · Enrique Rivas Zaldivar · Howard Sofen ·
Ignacio Dei-Cas · César Maldonado-García · Elkin O. Peñaranda ·
Luís Puig · Xiangyi Meng · Todd Fox · Adriana Guana

Published online: June 6, 2017
© The Author(s) 2017. This article is an open access publication

Erratum to: Adv Ther
DOI 10.1007/s12325-017-0521-z

Unfortunately, the given name and family name of the co-author Dr. César Maldonado García were incorrectly published in the original publication. The correct given name and family name should read as 'César' and 'Maldonado-García', respectively.

Also Dr. César Maldonado-García's affiliation should read as follows:

C. Maldonado-García
Centro Dermatológico "Dr. Ladislao de la Pascua", Mexico City, Mexico

The original article has been corrected.

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The online version of the original article can be found under doi:[10.1007/s12325-017-0521-z](https://doi.org/10.1007/s12325-017-0521-z).

S. Adsit (✉)
TCR Medical Corporation, San Diego, CA, USA
e-mail: sadsit@therapeuticsinc.com

E. R. Zaldivar
Dermos, Guatemala City, Guatemala

H. Sofen
UCLA School of Medicine, Los Angeles, CA, USA

I. Dei-Cas
Halitus, Buenos Aires, Argentina

C. Maldonado-García
Centro Dermatológico "Dr. Ladislao de la Pascua",
Mexico City, Mexico

E. O. Peñaranda
Riesgo de Fractura S.A., Bogota, Colombia

L. Puig
Hospital de la Santa Creu i Sant Pau, Universitat
Autònoma de Barcelona, Barcelona, Spain

X. Meng · A. Guana
Novartis Pharmaceuticals Corporation,
East Hanover, NJ, USA

T. Fox
Novartis Pharma AG, Basel, Switzerland